Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517464 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
A Phase 1 study of Neoplasm, sponsored by SynerGene Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT01517464 is a Phase 1 study of Neoplasm that has completed, run by SynerGene Therapeutics. The registered enrollment target is 13 participants, below the 201-participant average among 11 other Neoplasm trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01517464, a Phase 1 study of Neoplasm, has completed, sponsored by SynerGene Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I study designed to evaluate the safety and maximum tolerated dose (MTD) of SGT-94, a novel, tumor-targeted, systemic gene therapy agent for cancer. In addition, we will look for evidence of RB94 expression within tumor tissue after systemic administration of SGT-94.
Conditions Studied
Interventions
- GENETIC SGT-94
Study Locations (1)
Texas
- University of Texas, M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517464
The ClinicalTrials.gov registry entry for NCT01517464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 11 other Neoplasm trials with a reported enrollment target (94% lower). The listed sponsor is SynerGene Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which SGT-94 is the first listed.
NCT01517464 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01517464 about?
NCT01517464 is a clinical study titled "A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors". This is a Phase I study designed to evaluate the safety and maximum tolerated dose (MTD) of SGT-94, a novel, tumor-targeted, systemic gene therapy agent for cancer. In addition, we will look for evidence of RB94 expression within tumor tissue after systemic administration of SGT-94.
What is the current status of trial NCT01517464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2012-01. Estimated completion is 2015-12.
What conditions does trial NCT01517464 study?
This clinical trial studies the following conditions: Neoplasm.
What interventions are being tested in trial NCT01517464?
The interventions under investigation include: SGT-94 (GENETIC).
Who is sponsoring clinical trial NCT01517464?
This trial is sponsored by SynerGene Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01517464 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study of LY2835219 in Participants With Cancer
COMPLETED · Phase 1
-
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
COMPLETED · Phase 1
-
A Study of Galunisertib on the Immune System in Participants With Cancer
COMPLETED · Phase 1
-
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.